Astrazeneca (AZN) EBIT (2009 - 2026)

Astrazeneca's EBIT history runs 18 years deep, the most recent figure standing at $4.2 billion for Q1 2026.

• In Q1 2026, EBIT rose 15.57% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $14.3 billion (up 35.53% YoY), while the FY2025 annual figure was $13.7 billion, up 37.39% from the prior year.
• EBIT was $4.2 billion for Q1 2026 at Astrazeneca, up from $3.0 billion in the prior quarter.
• In the past five years, EBIT ranged from a high of $4.2 billion in Q1 2026 to a low of $539.0 million in Q2 2022.
• Historically, EBIT has averaged $2.3 billion across 5 years, with a median of $2.5 billion in 2023.
• Biggest YoY gain for EBIT was 474.66% in 2022; the steepest drop was 52.17% in 2022.
• A 5-year view of EBIT shows it stood at $1.1 billion in 2022, then grew by 12.8% to $1.2 billion in 2023, then surged by 64.99% to $2.0 billion in 2024, then soared by 46.27% to $3.0 billion in 2025, then jumped by 42.58% to $4.2 billion in 2026.
• The last three EBIT figures came in at $4.2 billion (Q1 2026), $3.0 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.